Page 35 - Personalised medicine of fluoropyrimidines using DPYD pharmacogenetics Carin Lunenburg

Prospective DPYD genotyping: ready for prime time
References
1. Offer SM, Wegner NJ, Fossum C, Wang K, Diasio RB. Phenotypic profiling of DPYD variations relevant to 5-fluorouracil sensitivity using real-time cellular analysis and in vitro measurement of 2 enzyme activity. Cancer Res. 2013;73(6):1958-1968.
2. Deenen MJ, Cats A, Mandigers CM, et al. [Prevention of severe toxicity from capecitabine, 5-fluorouracil and tegafur by screening for DPD-deficiency]. Ned Tijdschr Geneeskd. 2012;156(48):A4934.
3. Diasio RB, Johnson MR. The role of pharmacogenetics and pharmacogenomics in cancer chemotherapy with 5-fluorouracil. Pharmacology. 2000;61(3):199-203.
4. Rosmarin D, Palles C, Pagnamenta A, et al. A candidate gene study of capecitabine-related toxicity in colorectal cancer identifies new toxicity variants at DPYD and a putative role for ENOSF1 rather than TYMS. Gut. 2015;64(1):111-120.
5. Longley DB, Harkin DP, Johnston PG. 5-fluorouracil: mechanisms of action and clinical strategies. Nat Rev Cancer. 2003;3(5):330-338.
6. van Kuilenburg AB, Haasjes J, Richel DJ, et al. Clinical implications of dihydropyrimidine dehydrogenase (DPD) deficiency in patients with severe 5-fluorouracil-associated toxicity: identification of new mutations in the DPD gene. Clin Cancer Res. 2000;6(12):4705-4712.
7. van Kuilenburg AB, Maring JG. Evaluation of 5-fluorouracil pharmacokinetic models and therapeutic drug monitoring in cancer patients. Pharmacogenomics. 2013;14(7):799-811.
8. Rosmarin D, Palles C, Church D, et al. Genetic markers of toxicity from capecitabine and other
fluorouracil-based regimens: investigation in the QUASAR2 study, systematic review, and meta-
analysis. J Clin Oncol. 2014;32(10):1031-1039.
9. Terrazzino S, Cargnin S, Del RM, Danesi R, Canonico PL, Genazzani AA. DPYD IVS14+1G>A and
2846A>T genotyping for the prediction of severe fluoropyrimidine-related toxicity: a meta-
analysis. Pharmacogenomics. 2013;14(11):1255-1272.
10. Ciccolini J, Gross E, Dahan L, Lacarelle B, Mercier C. Routine dihydropyrimidine dehydrogenase
testing for anticipating 5-fluorouracil-related severe toxicities: hype or hope? Clin Colorectal
Cancer. 2010;9(4):224-228.
11. Lee AM, Shi Q, Pavey E, et al. DPYD variants as predictors of 5-fluorouracil toxicity in adjuvant
colon cancer treatment (NCCTG N0147). J Natl Cancer Inst. 2014;106(12).
12. Law L, Rogers J, Eng C. Delayed Presentation of DPD Deficiency in Colorectal Cancer. J Adv Pract
Oncol. 2014;5(3):205-210.
13. Saltz LB, Cox JV, Blanke C, et al. Irinotecan plus fluorouracil and leucovorin for metastatic
colorectal cancer. Irinotecan Study Group. N Engl J Med. 2000;343(13):905-914.
14. Diasio RB, Harris BE. Clinical pharmacology of 5-fluorouracil. Clin Pharmacokinet. 1989;16(4):215-
237.
15. Heggie GD, Sommadossi JP, Cross DS, Huster WJ, Diasio RB. Clinical pharmacokinetics of
5-fluorouracil and its metabolites in plasma, urine, and bile. Cancer Res. 1987;47(8):2203-2206.
16. Vallbohmer D, Yang DY, Kuramochi H, et al. DPD is a molecular determinant of capecitabine
efficacy in colorectal cancer. Int J Oncol. 2007;31(2):413-418.
17. Scartozzi M, Maccaroni E, Giampieri R, et al. 5-Fluorouracil pharmacogenomics: still rocking after
all these years? Pharmacogenomics. 2011;12(2):251-265.
18. McLeod HL, Collie-Duguid ESR, Vreken P, et al. Nomenclature for human DPYD alleles.
33